📊 LFST Key Takeaways
Is LFST a Good Investment? Thesis Analysis
LifeStance Health Group exhibits stagnant growth (0% YoY revenue and net income), coupled with critically thin profitability margins (0.7% net margin) that deliver minimal shareholder returns (0.6% ROE). While positive free cash flow and manageable leverage demonstrate operational viability, the company's capital inefficiency and zero growth trajectory present limited upside without fundamental operational improvement.
Why Buy LFST? Key Strengths
- Positive free cash flow of $110M with 7.7% FCF margin indicates operational cash generation capability
- Solid balance sheet with debt-to-equity ratio of 0.19x and $248.6M cash position provides financial flexibility
- Healthy liquidity with 1.65x current and quick ratios demonstrates near-term solvency
LFST Investment Risks to Consider
- Zero revenue and net income growth (0% YoY) indicates stagnation with no organic growth momentum
- Critically low profitability metrics: 0.7% net margin and 1.7% operating margin signal operational inefficiency and weak pricing power
- Abysmal returns on equity (0.6%) and assets (0.4%) demonstrate severe capital inefficiency and minimal shareholder value creation
- Weak interest coverage of 2.1x limits debt repayment flexibility and leaves minimal margin for operational deterioration
Key Metrics to Watch
- Revenue growth trajectory and whether company can achieve positive YoY growth
- Operating margin expansion and path to improving operational efficiency
- Return on equity improvement as indicator of capital allocation effectiveness
LFST Financial Metrics
💡 AI Analyst Insight
LifeStance Health Group, Inc. presents a mixed fundamental picture. Review the detailed metrics above to form your own investment thesis.
LFST Profitability Ratios
LFST vs Default Sector
How LifeStance Health Group, Inc. compares to Default sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is LFST Overvalued or Undervalued?
Based on fundamental analysis, LifeStance Health Group, Inc. has mixed fundamental signals relative to the Default sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
LFST Balance Sheet & Liquidity
LFST 5-Year Financial Trend & Growth Analysis
5-Year Trend Summary: LifeStance Health Group, Inc.'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-0.51 indicates the company is currently unprofitable.
LFST Growth Metrics (YoY)
LFST Quarterly Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $312.7M | $1.1M | $0.00 |
| Q2 2025 | $312.3M | -$3.1M | $-0.01 |
| Q1 2025 | $300.4M | $709.0K | $0.00 |
| Q3 2024 | $262.9M | -$6.0M | $-0.02 |
| Q2 2024 | $259.6M | -$23.3M | $-0.06 |
| Q1 2024 | $252.6M | -$21.1M | $-0.06 |
| Q3 2023 | $217.6M | -$37.9M | $-0.11 |
| Q2 2023 | $209.5M | -$45.5M | $-0.13 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
LFST Capital Allocation
LFST SEC 10-K & 10-Q Filing Analysis
Access official SEC EDGAR filings for LifeStance Health Group, Inc. (CIK: 0001845257)
📋 Recent SEC Filings
❓ Frequently Asked Questions about LFST
What is the AI rating for LFST?
LifeStance Health Group, Inc. (LFST) has an AI rating of SELL with 70% confidence, based on fundamental analysis of SEC EDGAR filings.
What are LFST's key strengths?
Claude: Positive free cash flow of $110M with 7.7% FCF margin indicates operational cash generation capability. Solid balance sheet with debt-to-equity ratio of 0.19x and $248.6M cash position provides financial flexibility.
What are the risks of investing in LFST?
Claude: Zero revenue and net income growth (0% YoY) indicates stagnation with no organic growth momentum. Critically low profitability metrics: 0.7% net margin and 1.7% operating margin signal operational inefficiency and weak pricing power.
What is LFST's revenue and growth?
LifeStance Health Group, Inc. reported revenue of $1.4B.
Does LFST pay dividends?
LifeStance Health Group, Inc. does not currently pay dividends.
Where can I find LFST SEC filings?
Official SEC filings for LifeStance Health Group, Inc. (CIK: 0001845257) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is LFST's EPS?
LifeStance Health Group, Inc. has a diluted EPS of $0.00.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is LFST a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, LifeStance Health Group, Inc. has a SELL rating with 70% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is LFST stock overvalued or undervalued?
Valuation metrics for LFST: ROE of 0.6% (sector avg: 15%), net margin of 0.7% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy LFST stock in 2026?
Our dual AI analysis gives LifeStance Health Group, Inc. a combined SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is LFST's free cash flow?
LifeStance Health Group, Inc.'s operating cash flow is $146.2M, with capital expenditures of $36.1M. FCF margin is 7.7%.
How does LFST compare to other Default stocks?
Vs Default sector averages: Net margin 0.7% (avg: 12%), ROE 0.6% (avg: 15%), current ratio 1.65 (avg: 1.8).